Gd 1806

Dkt. 41426-A-PCT-US/JPW/MSC/TAH

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Ron S. Israeli, et al.

U.S. Serial No.: 08/403,803

Filed : March 17, 1995

For : PROSTATE-SPECIFIC MEMBRANE ANTIGEN

1185 Avenue of the Americas New York, New York 10036

June 29, 1995

Assistant Commissioner for Patents Washington, D.C. 20231

Attn: Application Processing Division,

Special Processing and Correspondence Branch

sir:

COMMUNICATION IN RESPONSE TO NOTICE TO FILE MISSING PARTS OF APPLICATION UNDER 37 C.F.R. §§1.821-1.825

This Communication is submitted in response to the Notice to File Missing Parts of Application Under 37 C.F.R. §§1.821-1.825 issued by the United States Patent and Trademark Office on June 1, 1995 in connection with the above-identified patent application. A copy of the Notice is attached hereto as **Exhibit A**. A response to the June 1, 1995 Notice is due on July 1, 1995. Accordingly, this Communication is being timely filed.

The June 1, 1995 Notice stated that the subject application allegedly does not comply with the Sequence Rules because a copy of the "Sequence Listing" in computer readable form as required by 37 C.F.R. §1.821(e), and a Statement in Compliance Under 37 C.F.R. §1.821(f) have not been submitted.

In response, applicants maintain that a computer diskette containing a copy of the "Sequence Listing" in computer readable form as required under 37 C.F.R. §1.821(e) and a Statement of Compliance Under 37 C.F.R. §1.821(f) were submitted with the filing of PCT International Application No. PCT/US93/10624, international filing date November 5, 1993, of which the subject application is the national stage. As evidence applicants attach hereto as Exhibit B, a copy of a postcard bearing the mailroom

1867 #6 18132/010

10036

Applicants : Ron S. Israeli, et al.

U.S. Serial No.: 08/403,803

Filed : March 17, 1995

Page 2

stamp of the U.S. Receiving Office (RO/US) dated November 5, 1993, acknowledging receipt of the computer diskette containing a copy of the "Sequence Listing" in computer readable form under 37 C.F.R. §1.821(e), and Statement of Compliance Under 37 C.F.R. §1.821(f). Further, applicants attach hereto as **Exhibit C** a copy of the Statement of Compliance Under 37 C.F.R. §1.821(f) which was filed with International Application No. PCT/US93/10624 on November 5, 1993. Accordingly, applicants respectfully maintain that the subject application complies with the Sequence Rules Under 37 C.F.R. §§1.821-1.825.

For the convenience of the Patent and Trademark Office, applicants submit herewith a replacement computer diskette containing a copy of the "Sequence Listing" in computer readable form. The "Sequence Listing" appearing at pages 102-125 of the specification is identical to the "Sequence Listing" on the enclosed computer diskette. A Statement of Compliance stating that the "Sequence Listing" appearing at pages 102-125 of the specification and the content of the computer readable form of the "Sequence Listing" on the enclosed diskette are identical is attached hereto as **Exhibit D**.

Ron S. Israeli, et al. Applicants

08/403,803 U.S. Serial No.:

March 17, 1995 Filed

Page 3

No fee is deemed necessary in connection with the filing of this Communication. However, if any fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted

I hereby certify that this paper is being deposited this date with the U.S. Postal Service as first class mail addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

John P. White Registration No. 28,678

John P. White Registration No. 28,678 Attorney for Applicants Cooper & Dunham LLP 1185 Avenue of the Americas New York, New York 10036 (212) 278-0400

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

	1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
Ø	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(6
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
	7. Other:
App	olicant must provide:
	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"  An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification  A statement that the content of the paper and computer readable copies are the same and, where applicable, include its
For	new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d) questions regarding compliance with these requirements, please contact:
	Rules Interpretation, call (703) 308-1123

Please return a copy of this notice with your response.

For CRF submission help, call (703) 308-4212 For Patentin software help, call (703) 308-6856 Applicant Sloan-Kettering Institute For Cancer Research
Client Sloan(1747) File No. 41426-A-PCT JPW/AKC
Date 5 November 1993

Kindly acknowledge receipt of the accompanying
New International Patent Application Under the Patent Cooperation Treaty corresponding to Ron S. Israeli, et al., for
PROSTATE-SPECIFIC MEMBRANE ANTIGEN, designating EP, CA, JP, and
US (continuation-in-part), including Specification(125pp),
Claims(13pp), Abstract(lp), Figures(48pp), Transmittal letter,
PCT Request form(6pp), Fee Calculation Sheet, a Statement in
Accordance with 37C.F.R.Sect.1.821(f), and diskette, a check
for \$ 3,282.00, and Express Mail Certificate of Mailing dated
5 November 1993, bearing label No. IB535735079US.

by placing your receiving date stamp hereon and returning to us.

Date 5 November 1993 SA Rec'd PCT/PTC	05 NOV	1993	•
Ell No 41420	A-PCT	JPW.	AKC -
Applicant Sloan-Kettering Institute Fo	r Cancer	Rese	250

New International Patent Application Under the Patent Cooperation Treaty corresponding to Ron S. Israeli, et al., for PROSTATE-SPECIFIC MEMBRAGE ANDIGEN, designating EP, CA, JP, and US (continuation in part), including Specification(125pp), Claims(13pp), Abstract Figure 448pp), Transmittal letter, PCT Request form(6pp), Fee Claulation Sheet, a Statement in Accordance with 37C.F.R. Sect. 1(f), and diskette, a check for \$ 3,282.00, and Express Mail Certificate of Mailing dated, 5 November 1993, bearing label No. IB535735079US.

by placing your receiving date stamp hereon and returning to us. PCT/US 9 3 / 1 0 6 2 4

--

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Sloan-Kettering Institute for Cancer

Research, et al.

International

Application No.: Not Yet Known

International

Filing Date : 5 November 1993

FOr : PROSTATE-SPECIFIC MEMBRANE ANTIGEN

30 Rockefeller Plaza New York, New York 10112

5 November 1993

Honorable Commissioner of Patents and Trademarks Washington, D.C. 20231

Sir:

STATEMENT IN ACCORDANCE WITH 37 C.F.R. §1.821(f) FOR ABOVE-IDENTIFIED APPLICATION

Pursuant to 37 C.F.R. §1.821(f), I hereby certify that the contents of the sequence listings enclosed in the above-identified patent application papers and the contents of the computer readable form of the sequence listings are identical.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity if the application or any parent issued thereon.

Respectfully/submitted,

Mark S. Cohen

Law Clerk

c/o Cooper & Dunham
30 Rock fell r Plaza

New York, New York 10112

(212) 977-9550